Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients

Thomas Urup; Signe Regner Michaelsen; Lars Rønn Olsen; Anders Toft; Ib Jarle Christensen; Kirsten Grunnet; Ole Winther; Helle Broholm; Michael Kosteljanetz; Shohreh Issazadeh-Navikas; Hans Skovgaard Poulsen; Ulrik Niels Lassen

doi:10.1016/j.molonc.2016.05.005

Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients

Thomas Urup, Signe Regner Michaelsen, Lars Rønn Olsen, Anders Toft, Ib Jarle Christensen, Kirsten Grunnet, Ole Winther, Helle Broholm, Michael Kosteljanetz, Shohreh Issazadeh-Navikas, Hans Skovgaard Poulsen, Ulrik Niels Lassen

16 Citations (Scopus)

89 Downloads (Pure)

Original language	English
Journal	Molecular Oncology
Volume	10
Issue number	8
Pages (from-to)	1160-1168
ISSN	1574-7891
DOIs	https://doi.org/10.1016/j.molonc.2016.05.005
Publication status	Published - Oct 2016

Keywords

Predictive model
Angiotensin
Vascular normalization
Immune activation
Anti-angiogenic treatment
Glioblastoma
Antigen presentation

Access to Document

10.1016/j.molonc.2016.05.005

Urup_et_al-2016-Molecular_OncologyFinal published version, 1.22 MB

Cite this

Urup, T., Michaelsen, S. R., Olsen, L. R., Toft, A., Christensen, I. J., Grunnet, K., Winther, O., Broholm, H., Kosteljanetz, M., Issazadeh-Navikas, S., Poulsen, H. S., & Lassen, U. N. (2016). Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients. Molecular Oncology, 10(8), 1160-1168. https://doi.org/10.1016/j.molonc.2016.05.005

@article{b5ddaa759bb447a6930b7d06605e7c39,

title = "Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients",

keywords = "Predictive model, Angiotensin, Vascular normalization, Immune activation, Anti-angiogenic treatment, Glioblastoma, Antigen presentation",

author = "Thomas Urup and Michaelsen, {Signe Regner} and Olsen, {Lars R{\o}nn} and Anders Toft and Christensen, {Ib Jarle} and Kirsten Grunnet and Ole Winther and Helle Broholm and Michael Kosteljanetz and Shohreh Issazadeh-Navikas and Poulsen, {Hans Skovgaard} and Lassen, {Ulrik Niels}",

year = "2016",

month = oct,

doi = "10.1016/j.molonc.2016.05.005",

language = "English",

volume = "10",

pages = "1160--1168",

journal = "Molecular Oncology",

issn = "1574-7891",

publisher = "Elsevier",

number = "8",

}

TY - JOUR

T1 - Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients

AU - Urup, Thomas

AU - Michaelsen, Signe Regner

AU - Olsen, Lars Rønn

AU - Toft, Anders

AU - Christensen, Ib Jarle

AU - Grunnet, Kirsten

AU - Winther, Ole

AU - Broholm, Helle

AU - Kosteljanetz, Michael

AU - Issazadeh-Navikas, Shohreh

AU - Poulsen, Hans Skovgaard

AU - Lassen, Ulrik Niels

PY - 2016/10

Y1 - 2016/10

KW - Predictive model

KW - Angiotensin

KW - Vascular normalization

KW - Immune activation

KW - Anti-angiogenic treatment

KW - Glioblastoma

KW - Antigen presentation

U2 - 10.1016/j.molonc.2016.05.005

DO - 10.1016/j.molonc.2016.05.005

M3 - Journal article

C2 - 27262894

SN - 1574-7891

VL - 10

SP - 1160

EP - 1168

JO - Molecular Oncology

JF - Molecular Oncology

IS - 8

ER -

Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients

Keywords

Access to Document

Fingerprint

Cite this